A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Healthy
- Hepatic Impairment
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: RandomizedIntervention Model: Sequential AssignmentIntervention Model Description: The 3 groups will be sequentially studied. Dosing will start in the participants with mild hepatic impairment.Masking: None (Open Label)Primary Purpose: Other
Participation Requirements
- Age
- Between 18 years and 79 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04819464
- Collaborators
- Not Provided
- Investigators
- Study Director: Study Director Idorsia Pharmaceuticals Ltd.
Get Well Soon